The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment

Angiology

Volumn 63, Issue 1, 2012, Pages 67-75

  Christou, Georgios A ^a   Tellis, Constantinos C ^b   Elisaf, Moses S ^a   Tselepis, Alexandros D ^b   Kiortsis, Dimitrios N ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

apolipoprotein B; diet; fenofibrate; obesity; Retinol binding protein 4; small dense low density lipoprotein; triglycerides

Indexed keywords

APOLIPOPROTEIN B; CREATININE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL BINDING PROTEIN 4; RIMONABANT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LOW FAT DIET; MALE; OBESITY; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEINS B; CALORIC RESTRICTION; DIET, FAT-RESTRICTED; FEMALE; FENOFIBRATE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; PIPERIDINES; PYRAZOLES; RETINOL-BINDING PROTEINS, PLASMA;

EID: 82955194886     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711407628     Document Type: Article

References (39)

1. Blaner WS. Retinol-binding protein: the serum transport protein for vitamin A. Endocr Rev. 1989 ; 10 (3). 308-316 (Pubitemid 19223063)
2. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005 ; 436 (7049). 356-362 (Pubitemid 41065039)
3. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese and diabetic subjects. N Engl J Med. 2006 ; 354 (24). 2552-2563 (Pubitemid 43882351)
4. Ingelsson E, Sundstrom J, Melhus H, et al. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. Atherosclerosis. 2009 ; 206 (1). 38-39
5. Kloting N, Graham TE, Berndt J, et al. Serum Retinol-Binding Protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007 ; 6 (1). 79-87 (Pubitemid 46995778)
6. Jia W, Wu H, Bao Y, et al. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J Clin Endocrine Metab. 2007 ; 92 (8). 3224-3229 (Pubitemid 47236396)
7. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007 ; 176 (8). 1113-1120 (Pubitemid 46649735)
8. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002 ; 43 (9). 1363-1379
9. Florentin M, Tselepis AD, Elisaf MS, Rizos CV, Mikhailidis DP, Liberopoulos EN. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Curr Vasc Pharmacol. 2010 ; 8 (6). 820-830
10. Cabre A, Lazaro I, Girona J, et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease. J Intern Med. 2007 ; 262 (4). 496-503 (Pubitemid 47404369)
11. Mallat Z, Simon T, Benessiano J, et al. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab. 2009 ; 94 (1). 255-260
12. Ingelsson E, Lind L. Circulating retinol binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care. 2009 ; 32 (4). 733-735
13. Solini A, Santini E, Madec S, Rossi C, Muscelli E. Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens. 2009 ; 22 (9). 1001-1006
14. Park SE, Kim DH, Lee JH, et al. Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis. 2009 ; 204 (1). 23-25
15. Usui S, Ichimura M, Ikeda S, Okamoto M. Association between serum retinol-binding protein 4 and small dense low-density lipoprotein cholesterol levels in young adult women. Clinica Chimica Acta. 2009 ; 399 (1-2). 45-48
16. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421
17. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005 ; 51 (12). 2264-2273 (Pubitemid 41692569)
18. Florentin M, Liberopoulos EN, Filippatos TD, et al. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. Expert Opin Pharmacother. 2008 ; 9 (16). 2741-2750
19. Evangelou P, Tzotzas T, Christou G, Elisaf MS, Kiortsis DN. Does the presence of metabolic syndome influence weight loss in obese and overweight women?. Metab Syndr Relat Disord. 2010 ; 8 (2). 173-178
20. Stefan N, Hennige AM, Staiger H, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007 ; 30 (5). 1173-1178 (Pubitemid 46684644)
21. Ng TW, Watts GF, Barrett PH, Rye KA, Chan DC. Effect of weight loss on LDL and HDL kinetics in the Metabolic Syndrome: associations with changes in plasma retinol-binding protein-4 and adiponectin levels. Diabetes Care. 2007 ; 30 (11). 2945-2950 (Pubitemid 350083149)
22. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab. 2007 ; 92 (5). 1971-1974 (Pubitemid 46997219)
23. Reinehr T, Stoffel-Wagner B, Roth CL. Retinol-binding protein 4 and its relation to insulin resistance in obese children before and after weight loss. J Clin Endocrinol Metab. 2008 ; 93 (6). 2287-2293 (Pubitemid 351831549)
24. Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009 ; 44 (4). 297-309
25. Hermsdorff HH, Zulet MA, Abete I, Martínez JA. Discriminated benefits of a Mediterranean dietary pattern within a hypocaloric diet program on plasma RBP4 concentrations and other inflammatory markers in obese subjects. Endocrine. 2009 ; 36 (3). 445-451
26. Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein (a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis. 2001 ; 11 (3). 153-157 (Pubitemid 33686559)
27. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18 (6). 499-502
28. Von Eyatten M, Lepper PM, Liu D, et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007 ; 50 (9). 1930-1937 (Pubitemid 47222861)
29. Christensen EI, Moskaug JO, Vorum H, et al. Evidence for an essential role of megalin in transepithelial transport of retinol. J Am Soc Nephrol. 1999 ; 10 (4). 685-695 (Pubitemid 29149517)
30. Raila J, Willnow TE, Schweigert FJ. Megalin-mediated reuptake of retinol in the kidneys of mice is essential for vitamin A homeostasis. J Nutr. 2005 ; 135 (11). 2512-2516 (Pubitemid 43156588)
31. Piscator M. Early detection of tubular dysfunction. Kidney Int Suppl. 1991 ; 34: S15 - S17
32. Smith FR, Goodman DS. The effects of diseases of the liver, thyroid, and kidneys on the transport of vitamin A in human plasma. J Clin Invest. 1971 ; 50 (11). 2426-2436
33. Vahlquist A, Peterson PA, Wibell L. Metabolism of the vitamin A transporting protein complex. I. Turnover studies in normal persons and in patients with chronic renal failure. Eur J Clin Invest. 1973 ; 3 (4). 352-362
34. Ziegelmeier M, Bachmann A, Seeger J, et al. Serum levels of adipokine retinol-binding protein-4 in relation to renal function. Diabetes Care. 2007 ; 30 (10). 2588-2592 (Pubitemid 47547801)
35. Chang YH, Lin KD, Wang CL, Hsieh MC, Hsiao PJ, Shin SJ. Elevated serum retinol-binding protein 4 concentrations are associated with renal dysfunction and uric acid in type 2 diabetic patients. Diabetes Metab Res Rev. 2008 ; 24 (8). 629-634
36. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 ; 366 (9500). 1849-1861
37. Wu H, Wei L, Bao Y, et al. Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue. Am J Physiol Endocrinol Metab. 2009 ; 296 (4). 628-634
38. Mohapatra J, Sharma M, Singh S, et al. Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. J Pharm Pharmacol. 2009 ; 61 (11). 1493-1498
39. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005 ; 365 (9468). 1389-1397 (Pubitemid 40523733)